Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)
PHASE3CompletedINTERVENTIONAL
Enrollment
759
Participants
Timeline
Start Date
October 26, 2007
Primary Completion Date
June 3, 2009
Study Completion Date
June 3, 2009
Conditions
Prevention of : Herpes-Zoster
Interventions
BIOLOGICAL
Zostavax
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT00561080 - Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043) | Biotech Hunter | Biotech Hunter